Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Lowers PT on Myriad Genetics on New Medicare Code Values

Share:
Related MYGN
JPMorgan Checks In On Myriad Genetics Following 30% Rally
Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%

In a report published Monday, Jefferies reiterated its Buy rating on Myriad Genetics (NASDAQ: MYGN), but lowered its price target from $33.00 to $31.00.

Jefferies noted, “Noridian, MYGN's designated Medicare contractor, released the highly anticipated new molecular pathology reimbursement codes for CY13. The new codes suggest an 8% decrease and a 14% increase for MYGN's BRACAnalysis and COLARIS tests, respectively, relative to current commercial reimbursement rates. We are trimming our FY14 EPS forecast to $1.60 (from $1.65) on the disclosure. Our PT moves to $31 (from $33) on lower cash flow forecasts.”

Myriad Genetics closed on Friday at $25.46.

Latest Ratings for MYGN

DateFirmActionFromTo
Feb 2017Ladenburg ThalmannUpgradesSellNeutral
Jan 2017Deutsche BankInitiates Coverage OnSell
Nov 2016Stephens & Co.DowngradesOverweightEqual-Weight

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!